Vycellix Sweden Executive Leadership
Carin Dahlberg, Ph.D.
CHIEF OPERATING OFFICER
As a seasoned scientific executive, Dr. Dahlberg has served as Project Manager for the Gene & Cell Therapy Group at Karolinska Institutet (KI) since 2017 with extensive experience managing numerous projects advancing next-generation immune therapy programs including coordinating new collaborations with both industry and academia. Dr. Dahlberg earned her Ph.D. in Immunology from KI’s Department of Microbiology, Tumor and Cell Biology Department in 2015 and served a two-year postdoctoral fellowship at Nova Southeastern University (NSU) in Ft. Lauderdale, Florida, with a focus on developing novel strategies for NK cell therapies targeting Multiple Myeloma.
Vycellix Sweden Board of Directors
Evren Alici, M.D., Ph.D.
Head of Gene & Cell Therapy Group, Karolinska Institutet, Sweden
Group Leader, Hematology, Karolinska University Hospital, Sweden
Co-Director, NextGenNK Competence Center for Development of NK Cell Immunotherapy
Hans-Gustaf Ljunggren, M.D., Ph.D.
Professor, Department of Medicine, and former Dean of Research at Karolinska Institutet, Sweden
Member of the Nobel Assembly at Karolinska Institutet, Sweden
Co-Director, NextGenNK Competence Center for Development of NK Cell Immunotherapy
Arnika Wagner, Ph.D.
Assistant Professor & Group Leader
Genetic Modification of NK Cells for Optimized Functions Against Cancer
Department of Medicine, Karolinska Institutet, Sweden
Samuel Duffey, Esq.
Co-founder, Vycellix, Inc., USA
Former CEO, Biovest, Inc., USA
